

6 Literaturverzeichnis

1. Bretzel, R.G., K. Voigt, and H. Schatz, *The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus*. *Exp Clin Endocrinol Diabetes*, 1998. **106**(5): p. 369-72.
2. Nathan, D.M., *Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study*. *Lancet*, 1998. **352**(9131): p. 832-3.
3. Chrisholm, D.J., *The Diabetes Control and Complications Trial (DCCT). A milestone in diabetes management*. *Med J Aust*, 1993. **159**(11-12): p. 721-3.
4. Raskin, P., *The DCCT--finally!!* *J Diabetes Complications*, 1993. **7**(4): p. 214-5.
5. Kolb, H., et al., *Insulin therapy of prediabetes suppresses TH1 associated gene expression in BB rat pancreas*. *Autoimmunity*, 1997. **26**(1): p. 1-6.
6. Gerich, J.E., *The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity*. *Endocr Rev*, 1998. **19**(4): p. 491-503.
7. King, H., R.E. Aubert, and W.H. Herman, *Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections*. *Diabetes Care*, 1998. **21**(9): p. 1414-31.
8. Hauner, H., L. von Ferber, and I. Koster, *[Estimation of the incidence of diabetes in the Federal Republic of Germany based on insurance data. A secondary data analysis of a representative random sample of locally insured persons in the city of Dortmund]*. *Dtsch Med Wochenschr*, 1992. **117**(17): p. 645-50.
9. Hauner, H., *[Occurrence of diabetes mellitus in Germany]*. *Dtsch Med Wochenschr*, 1998. **123**(24): p. 777-82.
10. Grundy, S.M., et al., *Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association*. *Circulation*, 1999. **100**(10): p. 1134-46.
11. Andersen, A.R., et al., *Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study*. *Diabetologia*, 1983. **25**(6): p. 496-501.
12. Ritz, E. and A. Stefanski, *Diabetic nephropathy in type II diabetes*. *Am J Kidney Dis*, 1996. **27**(2): p. 167-94.
13. Ignarro, L.J., *Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein*. *Circ Res*, 1989. **65**(1): p. 1-21.

14. Azuma, H., M. Ishikawa, and S. Sekizaki, *Endothelium-dependent inhibition of platelet aggregation*. Br J Pharmacol, 1986. **88**(2): p. 411-5.
15. Freedman, J.E., et al., *Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene*. Circ Res, 1999. **84**(12): p. 1416-21.
16. Chen, C.H. and P.D. Henry, *Atherosclerosis as a microvascular disease: impaired angiogenesis mediated by suppressed basic fibroblast growth factor expression*. Proc Assoc Am Physicians, 1997. **109**(4): p. 351-61.
17. Chen, C.H., et al., *Inhibitory effects of hypercholesterolemia and ox-LDL on angiogenesis-like endothelial growth in rabbit aortic explants. Essential role of basic fibroblast growth factor*. Arterioscler Thromb Vasc Biol, 1997. **17**(7): p. 1303-12.
18. Furchgott, R.F. and J.V. Zawadzki, *The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine*. Nature, 1980. **288**(5789): p. 373-6.
19. Forstermann, U., et al., *Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control*. Biochem Pharmacol, 1995. **50**(9): p. 1321-32.
20. Li, H., et al., *Activation of protein kinase C alpha and/or epsilon enhances transcription of the human endothelial nitric oxide synthase gene*. Mol Pharmacol, 1998. **53**(4): p. 630-7.
21. Dimmeler, S., et al., *Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation*. Nature, 1999. **399**(6736): p. 601-5.
22. Fleming, I. and R. Busse, *Signal transduction of eNOS activation*. Cardiovasc Res, 1999. **43**(3): p. 532-41.
23. Papapetropoulos, A., R.D. Rudic, and W.C. Sessa, *Molecular control of nitric oxide synthases in the cardiovascular system*. Cardiovasc Res, 1999. **43**(3): p. 509-20.
24. Cosentino, F., et al., *Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats*. J Clin Invest, 1998. **101**(7): p. 1530-7.
25. Vergnani, L., et al., *Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : key role of L-arginine availability*. Circulation, 2000. **101**(11): p. 1261-6.

26. Libby, P., *Inflammation in atherosclerosis*. Nature, 2002. **420**(6917): p. 868-74.
27. Topper, J.N., et al., *Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress*. Proc Natl Acad Sci U S A, 1996. **93**(19): p. 10417-22.
28. De Caterina, R., et al., *Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines*. J Clin Invest, 1995. **96**(1): p. 60-8.
29. Nagel, T., et al., *Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells*. J Clin Invest, 1994. **94**(2): p. 885-91.
30. Libby, P., P.M. Ridker, and A. Maseri, *Inflammation and atherosclerosis*. Circulation, 2002. **105**(9): p. 1135-43.
31. Hansson, G.K., et al., *Innate and adaptive immunity in the pathogenesis of atherosclerosis*. Circ Res, 2002. **91**(4): p. 281-91.
32. Young, J.L., P. Libby, and U. Schonbeck, *Cytokines in the pathogenesis of atherosclerosis*. Thromb Haemost, 2002. **88**(4): p. 554-67.
33. Ross, R., *Atherosclerosis--an inflammatory disease*. N Engl J Med, 1999. **340**(2): p. 115-26.
34. Libby, P., *Current concepts of the pathogenesis of the acute coronary syndromes*. Circulation, 2001. **104**(3): p. 365-72.
35. Wilcox, J.N., et al., *Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque*. Proc Natl Acad Sci U S A, 1989. **86**(8): p. 2839-43.
36. Rosenson, R.S. and W. Koenig, *Utility of inflammatory markers in the management of coronary artery disease*. Am J Cardiol, 2003. **92**(1A): p. 10i-8i.
37. Blake, G.J. and P.M. Ridker, *Inflammatory bio-markers and cardiovascular risk prediction*. J Intern Med, 2002. **252**(4): p. 283-94.
38. Griending, K.K., D. Sorescu, and M. Ushio-Fukai, *NAD(P)H oxidase: role in cardiovascular biology and disease*. Circ Res, 2000. **86**(5): p. 494-501.

39. Warnholtz, A., et al., *Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system.* *Circulation*, 1999. **99**(15): p. 2027-33.
40. Meyer, J.W. and M.E. Schmitt, *A central role for the endothelial NADPH oxidase in atherosclerosis.* *FEBS Lett*, 2000. **472**(1): p. 1-4.
41. Drexler, H., *Nitric oxide and coronary endothelial dysfunction in humans.* *Cardiovasc Res*, 1999. **43**(3): p. 572-9.
42. Niu, X.F., C.W. Smith, and P. Kubes, *Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils.* *Circ Res*, 1994. **74**(6): p. 1133-40.
43. Radomski, M.W., R.M. Palmer, and S. Moncada, *The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium.* *Biochem Biophys Res Commun*, 1987. **148**(3): p. 1482-9.
44. Haller, H., *Endothelial function. General considerations.* *Drugs*, 1997. **53 Suppl 1**: p. 1-10.
45. Gimbrone, M.A., Jr., *Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis.* *Am J Cardiol*, 1995. **75**(6): p. 67B-70B.
46. Poole, J.C. and H.W. Florey, *Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits.* *J Pathol Bacteriol*, 1958. **75**(2): p. 245-51.
47. Butcher, E.C., *Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity.* *Cell*, 1991. **67**(6): p. 1033-6.
48. Cotran, R.S. and T. Mayadas-Norton, *Endothelial adhesion molecules in health and disease.* *Pathol Biol (Paris)*, 1998. **46**(3): p. 164-70.
49. Springer, T.A., *The sensation and regulation of interactions with the extracellular environment: the cell biology of lymphocyte adhesion receptors.* *Annu Rev Cell Biol*, 1990. **6**: p. 359-402.
50. Gu, L., et al., *Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice.* *Mol Cell*, 1998. **2**(2): p. 275-81.
51. Boring, L., et al., *Decreased lesion formation in CCR2^{-/-} mice reveals a role for chemokines in the initiation of atherosclerosis.* *Nature*, 1998. **394**(6696): p. 894-7.

52. Mach, F., et al., *Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells*. J Clin Invest, 1999. **104**(8): p. 1041-50.
53. Blann, A.D. and G.Y. Lip, *Raised levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the plasma of patients with ischaemic heart disease and hyperlipidaemia*. Atherosclerosis, 1998. **141**(1): p. 177-8.
54. Bluher, M., et al., *Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes*. Diabetologia, 2002. **45**(2): p. 210-6.
55. Carter, A.M. and P.J. Grant, *Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus*. Diabet Med, 1997. **14**(6): p. 423-32.
56. Tummala, P.E., et al., *Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis*. Circulation, 1999. **100**(11): p. 1223-9.
57. Tsao, P.S., et al., *Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1*. Circulation, 1996. **94**(7): p. 1682-9.
58. Qian, H., et al., *Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits*. Circulation, 1999. **99**(23): p. 2979-82.
59. Theilmeyer, G., et al., *Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine*. Arterioscler Thromb Vasc Biol, 1997. **17**(12): p. 3557-64.
60. Bath, P.M., et al., *Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro*. Arterioscler Thromb, 1991. **11**(2): p. 254-60.
61. Cooper, M.E., *The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications*. Am J Hypertens, 2004. **17**(11 Pt 2): p. 16S-20S; quiz A2-4.
62. O'Driscoll, G., et al., *Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus*. J Am Coll Cardiol, 1999. **33**(6): p. 1506-11.

63. Candido, R., et al., *Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis*. *Circulation*, 2004. **109**(12): p. 1536-42.
64. Sawicki, P.T. and A. Siebenhofer, *Betablocker treatment in diabetes mellitus*. *J Intern Med*, 2001. **250**(1): p. 11-7.
65. Kranzhofer, R., et al., *Angiotensin induces inflammatory activation of human vascular smooth muscle cells*. *Arterioscler Thromb Vasc Biol*, 1999. **19**(7): p. 1623-9.
66. Pliquett, R., et al., *Neurohumoral stimulation in type-2-diabetes as an emerging disease concept*. *Cardiovasc Diabetol*, 2004. **3**(1): p. 4.
67. Kaplan, J.R., et al., *Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet*. *Circulation*, 1987. **76**(6): p. 1364-72.
68. Pettersson, K., et al., *Experimental sympathetic activation causes endothelial injury in the rabbit thoracic aorta via beta 1-adrenoceptor activation*. *Circ Res*, 1990. **67**(4): p. 1027-34.
69. Obermuller, N., et al., *Distribution of angiotensin II receptor subtypes in rat brain nuclei*. *Neurosci Lett*, 1991. **132**(1): p. 11-5.
70. Stoll, M., et al., *The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells*. *J Clin Invest*, 1995. **95**(2): p. 651-7.
71. Steckelings, U.M., S.P. Bottari, and T. Unger, *Angiotensin receptor subtypes in the brain*. *Trends Pharmacol Sci*, 1992. **13**(9): p. 365-8.
72. Rajagopalan, S., et al., *Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone*. *J Clin Invest*, 1996. **97**(8): p. 1916-23.
73. Linz, W., et al., *Interactions among ACE, kinins and NO*. *Cardiovasc Res*, 1999. **43**(3): p. 549-61.
74. Benzing, T., et al., *Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells*. *Circulation*, 1999. **99**(15): p. 2034-40.

75. Hornig, B., C. Kohler, and H. Drexler, *Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans*. *Circulation*, 1997. **95**(5): p. 1115-8.
76. Tsutsumi, Y., et al., *Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation*. *J Clin Invest*, 1999. **104**(7): p. 925-35.
77. Miyamoto, M.I., et al., *Effect of alpha-adrenergic stimulation on regional contractile function and myocardial blood flow with and without ischemia*. *Circulation*, 1991. **84**(4): p. 1715-24.
78. Zierhut, W. and H.G. Zimmer, *Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy*. *Circ Res*, 1989. **65**(5): p. 1417-25.
79. Communal, C., et al., *Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein*. *Circulation*, 1999. **100**(22): p. 2210-2.
80. Aromaa, A., A. Reunanen, and K. Pyorala, *Hypertension and mortality in diabetic and non-diabetic Finnish men*. *J Hypertens Suppl*, 1984. **2**(3): p. S205-7.
81. UKPDS, *Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38*. *UK Prospective Diabetes Study Group*. *Bmj*, 1998. **317**(7160): p. 703-13.
82. Hansson, L., et al., *Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial*. *HOT Study Group*. *Lancet*, 1998. **351**(9118): p. 1755-62.
83. Reaven, G.M., H. Lithell, and L. Landsberg, *Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system*. *N Engl J Med*, 1996. **334**(6): p. 374-81.
84. Gress, T.W., et al., *Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus*. *Atherosclerosis Risk in Communities Study*. *N Engl J Med*, 2000. **342**(13): p. 905-12.

85. Von Arnim, T., *Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up.* J Am Coll Cardiol, 1996. **28**(1): p. 20-4.
86. Jonas, M., et al., *Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group.* Am J Cardiol, 1996. **77**(15): p. 1273-7.
87. Herr, R.R., et al., *Isolation and characterization of streptozotocin.* Antibiot Annu, 1959. **7**: p. 236-40.
88. Arison, R.N. and E.L. Feudale, *Induction of renal tumour by streptozotocin in rats.* Nature, 1967. **214**(94): p. 1254-5.
89. Rakieten, N., M.L. Rakieten, and M.V. Nadkarni, *Studies on the diabetogenic action of streptozotocin (NSC-37917).* Cancer Chemother Rep, 1963. **29**: p. 91-8.
90. Dorenkamp, M., et al., *Protection against oxidative stress in diabetic rats: Role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism.* Eur J Pharmacol, 2005.
91. Giorgino, F., J.H. Chen, and R.J. Smith, *Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight nonreceptor protein in vivo in skeletal muscle of streptozotocin-induced diabetic rats: effects of insulin and glucose.* Endocrinology, 1992. **130**(3): p. 1433-44.
92. Van Voorhis, K., et al., *Effect of chemically induced diabetes mellitus on glutamine transport in rat intestine.* Gastroenterology, 1990. **98**(4): p. 862-6.
93. Riva, E., et al., *Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes.* Pharmacol Res, 1998. **37**(3): p. 233-40.
94. Tomlinson, K.C., S.M. Gardiner, and T. Bennett, *Diabetes mellitus in Brattleboro rats: cardiovascular, fluid, and electrolyte status.* Am J Physiol, 1989. **256**(6 Pt 2): p. R1279-85.
95. Angulo, J., et al., *Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats.* Naunyn Schmiedebergs Arch Pharmacol, 1998. **358**(5): p. 529-37.
96. Jensen, T., et al., *Features of endothelial dysfunction in early diabetic nephropathy.* Lancet, 1989. **1**(8636): p. 461-3.

97. Stehouwer, C.D., et al., *Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus*. *Lancet*, 1992. **340**(8815): p. 319-23.
98. Rees, D.D., et al., *Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo*. *Br J Pharmacol*, 1990. **101**(3): p. 746-52.
99. Hsu, S.M. and L. Raine, *Protein A, avidin, and biotin in immunohistochemistry*. *J Histochem Cytochem*, 1981. **29**(11): p. 1349-53.
100. Tschöpe, C., et al., *Angiotensin AT2 Receptor Deficiency After Myocardial Infarction: Its Effects on Cardiac Function and Fibrosis Depend on the Stimulus*. *Cell Biochem Biophys*, 2005. **43**(1): p. 45-52.
101. Noutsias, M., et al., *Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy*. *Med Sci Monit*, 2002. **8**(5): p. MT59-71.
102. Kuhl, U., M. Noutsias, and H.P. Schultheiss, *Immunohistochemistry in dilated cardiomyopathy*. *Eur Heart J*, 1995. **16 Suppl O**: p. 100-6.
103. Kiff, R.J., et al., *Selective impairment of hindquarters vasodilator responses to bradykinin in conscious Wistar rats with streptozotocin-induced diabetes mellitus*. *Br J Pharmacol*, 1991. **103**(2): p. 1357-62.
104. Kamata, K., et al., *Endothelium-dependent vasodilator effects of platelet activating factor on rat resistance vessels*. *Br J Pharmacol*, 1989. **98**(4): p. 1360-4.
105. Lash, J.M. and H.G. Bohlen, *Structural and functional origins of suppressed acetylcholine vasodilation in diabetic rat intestinal arterioles*. *Circ Res*, 1991. **69**(5): p. 1259-68.
106. Koltai, M.Z., et al., *Characteristics of coronary endothelial dysfunction in experimental diabetes*. *Cardiovasc Res*, 1997. **34**(1): p. 157-63.
107. Sikorski, B.W., W.C. Hodgson, and R.G. King, *Effects of haemoglobin and N-nitro-L-arginine on constrictor and dilator responses of aortic rings from streptozotocin diabetic rats*. *Eur J Pharmacol*, 1993. **242**(3): p. 275-82.
108. Calver, A., J. Collier, and P. Vallance, *Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes*. *J Clin Invest*, 1992. **90**(6): p. 2548-54.

109. Elliott, T.G., et al., *Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria*. Clin Sci (Lond), 1993. **85**(6): p. 687-93.
110. Ludmer, P.L., et al., *Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries*. N Engl J Med, 1986. **315**(17): p. 1046-51.
111. Kinlay, S. and P. Ganz, *Role of endothelial dysfunction in coronary artery disease and implications for therapy*. Am J Cardiol, 1997. **80**(9A): p. 111-161.
112. Ganz, P. and J.A. Vita, *Testing endothelial vasomotor function: nitric oxide, a multipotent molecule*. Circulation, 2003. **108**(17): p. 2049-53.
113. Widlansky, M.E., et al., *The clinical implications of endothelial dysfunction*. J Am Coll Cardiol, 2003. **42**(7): p. 1149-60.
114. Lerman, A. and A.M. Zeiher, *Endothelial function: cardiac events*. Circulation, 2005. **111**(3): p. 363-8.
115. Kado, S., et al., *Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells*. Life Sci, 2001. **68**(7): p. 727-37.
116. Kim, J.A., et al., *Evidence that glucose increases monocyte binding to human aortic endothelial cells*. Diabetes, 1994. **43**(9): p. 1103-7.
117. Majewska, E., et al., *Role of tyrosine kinase enzymes in TNF-alpha and IL-1 induced expression of ICAM-1 and VCAM-1 on human umbilical vein endothelial cells*. Scand J Immunol, 1997. **45**(4): p. 385-92.
118. Daxecker, H., et al., *Endothelial adhesion molecule expression in an in vitro model of inflammation*. Clin Chim Acta, 2002. **325**(1-2): p. 171-5.
119. Fasching, P., W. Waldhausl, and O.F. Wagner, *Elevated circulating adhesion molecules in NIDDM--potential mediators in diabetic macroangiopathy*. Diabetologia, 1996. **39**(10): p. 1242-4.
120. Fasching, P., et al., *Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus*. J Clin Endocrinol Metab, 1996. **81**(12): p. 4313-7.
121. Steiner, M., et al., *Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control*. Thromb Haemost, 1994. **72**(6): p. 979-84.

122. Castelli, W.P., *Lipids, risk factors and ischaemic heart disease*. Atherosclerosis, 1996. **124 Suppl**: p. S1-9.
123. Ridker, P.M., et al., *Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men*. N Engl J Med, 1997. **336**(14): p. 973-9.
124. Ridker, P.M., et al., *Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease*. Circulation, 1998. **97**(5): p. 425-8.
125. Ridker, P.M., et al., *C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women*. N Engl J Med, 2000. **342**(12): p. 836-43.
126. Kreuzer, K.A., et al., *A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-alpha*. J Immunol Methods, 1996. **195**(1-2): p. 49-54.
127. Biasucci, L.M., et al., *Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events*. Circulation, 1999. **99**(16): p. 2079-84.
128. Ridker, P.M., et al., *Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men*. Circulation, 2000. **101**(15): p. 1767-72.
129. Libby, P., *Atherosclerosis: the new view*. Sci Am, 2002. **286**(5): p. 46-55.
130. Ridker, P.M., et al., *Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men*. Lancet, 1998. **351**(9096): p. 88-92.
131. Moncada, S. and E.A. Higgs, *Endogenous nitric oxide: physiology, pathology and clinical relevance*. Eur J Clin Invest, 1991. **21**(4): p. 361-74.
132. van der Veen, R.C., *Nitric oxide and T helper cell immunity*. Int Immunopharmacol, 2001. **1**(8): p. 1491-500.
133. Beck, K.F., et al., *Inducible NO synthase: role in cellular signalling*. J Exp Biol, 1999. **202**(Pt 6): p. 645-53.
134. Laursen, J.B., et al., *Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin*. Circulation, 2001. **103**(9): p. 1282-8.

135. Ozaki, M., et al., *Overexpression of endothelial nitric oxide synthase in endothelial cells is protective against ischemia-reperfusion injury in mouse skeletal muscle*. Am J Pathol, 2002. **160**(4): p. 1335-44.
136. Landmesser, U., et al., *Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension*. J Clin Invest, 2003. **111**(8): p. 1201-9.
137. Hink, U., et al., *Mechanisms underlying endothelial dysfunction in diabetes mellitus*. Circ Res, 2001. **88**(2): p. E14-22.
138. Guzik, T.J., et al., *Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase*. Circulation, 2002. **105**(14): p. 1656-62.
139. Oyadomari, S., et al., *Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats*. Nitric Oxide, 2001. **5**(3): p. 252-60.
140. Alp, N.J. and K.M. Channon, *Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease*. Arterioscler Thromb Vasc Biol, 2004. **24**(3): p. 413-20.
141. Meininger, C.J., et al., *Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency*. Biochem J, 2000. **349**(Pt 1): p. 353-6.
142. Stangl, V., et al., *Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway*. Faseb J, 2004. **18**(2): p. 272-9.
143. Beckman, J.S. and W.H. Koppenol, *Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly*. Am J Physiol, 1996. **271**(5 Pt 1): p. C1424-37.
144. Ceriello, A., et al., *Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress*. Diabetologia, 2001. **44**(7): p. 834-8.
145. Cosentino, F., et al., *High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells*. Circulation, 1997. **96**(1): p. 25-8.
146. Hsueh, W.A. and M.J. Quinones, *Role of endothelial dysfunction in insulin resistance*. Am J Cardiol, 2003. **92**(4A): p. 10J-17J.

147. Mollnau, H., et al., *Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling*. *Circ Res*, 2002. **90**(4): p. E58-65.
148. Bojunga, J., et al., *Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats*. *Diabetologia*, 2004. **47**(12): p. 2072-2080.
149. Thomsen, K., I. Rubin, and M. Lauritzen, *NO- and non-NO-, non-prostanoid-dependent vasodilatation in rat sciatic nerve during maturation and developing experimental diabetic neuropathy*. *J Physiol*, 2002. **543**(Pt 3): p. 977-93.
150. Bardell, A.L. and K.M. MacLeod, *Evidence for inducible nitric-oxide synthase expression and activity in vascular smooth muscle of streptozotocin-diabetic rats*. *J Pharmacol Exp Ther*, 2001. **296**(2): p. 252-9.
151. Smith, J.M., D.J. Paulson, and F.D. Romano, *Inhibition of nitric oxide synthase by L-NAME improves ventricular performance in streptozotocin-diabetic rats*. *J Mol Cell Cardiol*, 1997. **29**(9): p. 2393-402.
152. Tannous, M., et al., *Evidence for iNOS-dependent peroxynitrite production in diabetic platelets*. *Diabetologia*, 1999. **42**(5): p. 539-44.
153. Cai, S., et al., *Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation*. *Diabetologia*, 2005. **48**(9): p. 1933-40.
154. Rajagopalan, S., et al., *Effect of losartan in aging-related endothelial impairment*. *Am J Cardiol*, 2002. **89**(5): p. 562-6.
155. Rahman, S.T., et al., *Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation)*. *Am J Cardiol*, 2002. **89**(6): p. 686-90.
156. Jilma, B., et al., *Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1*. *Clin Sci (Lond)*, 2002. **103**(2): p. 131-6.
157. Schram, M.T., et al., *Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive*

- type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial.* J Hum Hypertens, 2005.
158. Campbell, D.J., H. Krum, and M.D. Esler, *Losartan increases bradykinin levels in hypertensive humans.* Circulation, 2005. **111**(3): p. 315-20.
159. Morigi, M., et al., *Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion.* J Clin Invest, 1998. **101**(9): p. 1905-15.
160. Skurk, T., V. van Harmelen, and H. Hauner, *Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB.* Arterioscler Thromb Vasc Biol, 2004. **24**(7): p. 1199-203.
161. Michel, J.B., [*Renin-angiotensin system and vascular remodelling*]. Med Sci (Paris), 2004. **20**(4): p. 409-13.
162. Phillips, M.I. and S. Kagiyama, *Angiotensin II as a pro-inflammatory mediator.* Curr Opin Investig Drugs, 2002. **3**(4): p. 569-77.
163. Esteban, V., et al., *Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction.* J Am Soc Nephrol, 2004. **15**(6): p. 1514-29.
164. Rosei, E.A., et al., *Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.* J Hypertens, 2005. **23**(2): p. 435-44.
165. Fan, Q., et al., *Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.* Nephrol Dial Transplant, 2004. **19**(12): p. 3012-20.
166. Deng, L.Y. and E.L. Schiffrin, *Effect of antihypertensive treatment on response to endothelin of resistance arteries of hypertensive rats.* J Cardiovasc Pharmacol, 1993. **21**(5): p. 725-31.
167. Intengan, H.D. and E.L. Schiffrin, *Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries.* J Cardiovasc Pharmacol, 2000. **35**(5): p. 763-8.

168. Schiffrin, E.L., L.Y. Deng, and P. Laroche, *Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension*. Hypertension, 1994. **23**(1): p. 83-91.
169. Thybo, N.K., et al., *Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension*. Hypertension, 1995. **25**(4 Pt 1): p. 474-81.
170. Guth, B.D., et al., *Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs*. Circ Res, 1987. **60**(5): p. 738-46.
171. Buck, J.D., et al., *Changes in ischemic blood flow distribution and dynamic severity of a coronary stenosis induced by beta blockade in the canine heart*. Circulation, 1981. **64**(4): p. 708-15.
172. Matsuzaki, M., et al., *Effects of beta-blockade on regional myocardial flow and function during exercise*. Am J Physiol, 1984. **247**(1 Pt 2): p. H52-60.
173. Schulz, R., et al., *Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol*. J Cardiovasc Pharmacol, 1995. **25**(2): p. 216-28.
174. Freemantle, N., et al., *beta Blockade after myocardial infarction: systematic review and meta regression analysis*. Bmj, 1999. **318**(7200): p. 1730-7.
175. Kalinowski, L., et al., *Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action*. Circulation, 2003. **107**(21): p. 2747-52.
176. Van de Water, A., et al., *Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist*. J Cardiovasc Pharmacol, 1988. **11**(5): p. 552-63.
177. Bowman, A.J., C.P. Chen, and G.A. Ford, *Nitric oxide mediated venodilator effects of nebivolol*. Br J Clin Pharmacol, 1994. **38**(3): p. 199-204.
178. Cockcroft, J.R., et al., *Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism*. J Pharmacol Exp Ther, 1995. **274**(3): p. 1067-71.

179. Broeders, M.A., et al., *Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production*. *Circulation*, 2000. **102**(6): p. 677-84.
180. Bell, D.S., *Advantages of a third-generation beta-blocker in patients with diabetes mellitus*. *Am J Cardiol*, 2004. **93**(9A): p. 49B-52B.
181. Fahlbusch, S.A., et al., *Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers*. *Eur J Clin Pharmacol*, 2004. **60**(2): p. 83-8.
182. Mayer, B., et al., *Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels*. *Int J Cardiol*, 2005. **103**(2): p. 182-6.